English

REGULUS THERAPEUTICS INC.

EDGAR

RGLS Quarterly report (10-Q) · filed 2025-05-08

88 filing records in this dataset, filed from 2012-08-17 to 2025-05-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2021 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-7.83 million USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -24128000 USD Source
Operating Cash Flow: -16297000 USD Source

Free cash flow

-7.87 million USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -24128000 USD Source
Operating Cash Flow: -16297000 USD Source
Capital Expenditure: 251000 USD Source
Capital Expenditure: 210000 USD Source

Cash and cash equivalents: 49.5 million USD 2025-03-31 Source
Exact value

49460000 USD
Long-term debt including current maturities: 0 USD 2017-12-31 Source
Exact value

0 USD
Shares outstanding: 66.3 million shares 2025-03-31 Source
Exact value

66283250 shares

Reported share-count change

1.25% · 818 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

65465251 shares · 2024-03-31· Source
66283250 shares · 2025-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Revenue: 0 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 0 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 0 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 0 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 0 USD · 2021-01-01 – 2021-09-30 Source

Net income

-47.5 million USD

2024-04-01 – 2025-03-31

Exact inputs and evidence

Net income: -11036000 USD · 2024-04-01 – 2024-06-30 Source
Net income: -14062000 USD · 2024-07-01 – 2024-09-30 Source
Net income: -46358000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -33567000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -9634000 USD · 2025-01-01 – 2025-03-31 Source

Operating cash flow

-43.5 million USD

2024-04-01 – 2025-03-31

Exact inputs and evidence

Operating cash flow: -20379000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -8742000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -29828000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -20379000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -41673000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -29828000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -10613000 USD · 2025-01-01 – 2025-03-31 Source

Capital expenditure

111 thousand USD

2024-04-01 – 2025-03-31

Exact inputs and evidence

Capital expenditure: 312000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 229000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 340000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 312000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 340000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 340000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 0 USD · 2025-01-01 – 2025-03-31 Source

Free cash flow

-43.7 million USD

2024-04-01 – 2025-03-31

Exact inputs and evidence

Operating cash flow: -20379000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -8742000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -29828000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -20379000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -41673000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -29828000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -10613000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 312000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 229000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 340000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 312000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 340000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 340000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 0 USD · 2025-01-01 – 2025-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-05-08.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2021-12-31
Operating income: 11 of 11 periods available· newest 2024-12-31
Net income: 11 of 11 periods available· newest 2024-12-31
Operating cash flow: 11 of 11 periods available· newest 2024-12-31
Capital expenditure: 11 of 11 periods available· newest 2024-12-31
Total assets: 11 of 11 periods available· newest 2024-12-31
Total liabilities: 11 of 11 periods available· newest 2024-12-31
Current assets: 11 of 11 periods available· newest 2024-12-31
Current liabilities: 11 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2017-12-31
Shares outstanding: 11 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 16.32 million

Prior period

−USD 30.04 million

2023-01-01 – 2023-12-31
Current period

−USD 46.36 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-46358000 − -30037000 = -16321000 USD

-30037000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-46358000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · REGULUS THERAPEUTICS INC. · 2024-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Year-over-year change in Net income: -16321000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -46358000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#963050 Filing: 000162828025012627 Input fundies:NetIncome: -30037000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#963833 Filing: 000162828025012627
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 14.91 million

Prior period

−USD 26.77 million

2023-01-01 – 2023-12-31
Current period

−USD 41.67 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-41673000 − -26768000 = -14905000 USD

-26768000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-41673000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · REGULUS THERAPEUTICS INC. · 2024-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Year-over-year change in Operating cash flow: -14905000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -41673000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#984534 Filing: 000162828025012627 Input fundies:OperatingCashFlow: -26768000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#985197 Filing: 000162828025012627
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-44.5%

Prior period

USD 613,000

2023-01-01 – 2023-12-31
Current period

USD 340,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

340000 − 613000 = -273000 USD

613000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
340000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · REGULUS THERAPEUTICS INC. · 2024-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Year-over-year change in Capital expenditure: -273000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 340000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#989699 Filing: 000162828025012627 Input fundies:CapitalExpenditure: 613000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#990263 Filing: 000162828025012627
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 0
Operating costs Derived USD 27.82 million
Operating income −USD 27.82 million
Tax, interest and other Derived −USD 8,000
Net income −USD 27.81 million

Cash

Operating cash flow −USD 24.13 million
Capital expenditure USD 251,000
Free cash flow Derived −USD 24.38 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Operating loss: operating costs were 364% of revenue.
2016 Operating loss: operating costs were 6,926% of revenue.
2017 Operating loss: operating costs were 97,504% of revenue.
2018 Operating loss: operating costs were 65,049% of revenue.
2019 Operating loss: operating costs were 346% of revenue.
2020 Operating loss: operating costs were 241% of revenue.
2021 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	20759000	75517000 Derived	-54758000	990000 Derived	-55748000	-51222000 Derived	Source 2015-01-01 – 2015-12-31: 20759000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -54758000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -55748000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -49859000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 1363000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	1194000	82696000 Derived	-81502000	334000 Derived	-81836000	-57795000 Derived	Source 2016-01-01 – 2016-12-31: 1194000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -81502000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -81836000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -56882000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 913000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	72000	70203000 Derived	-70131000	1774000 Derived	-71905000	-59076000 Derived	Source 2017-01-01 – 2017-12-31: 72000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -70131000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -71905000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -58773000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 303000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	72000	46835000 Derived	-46763000	1946000 Derived	-48709000	-43295000 Derived	Source 2018-01-01 – 2018-12-31: 72000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -46763000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -48709000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -43273000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 22000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	6832000	23666000 Derived	-16834000	1758000 Derived	-18592000	-20042000 Derived	Source 2019-01-01 – 2019-12-31: 6832000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -16834000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -18592000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -19821000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 221000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	10006000	24161000 Derived	-14155000	1575000 Derived	-15730000	-12536000 Derived	Source 2020-01-01 – 2020-12-31: 10006000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -14155000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -15730000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -12536000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	27816000 Derived	-27816000	-8000 Derived	-27808000	-24379000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -27816000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -27808000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -24128000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 251000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	7669000	Revenue: 7669000 Open source
20152015-12-31	Revenue	20759000	Revenue: 20759000 Open source
20162016-12-31	Revenue	1194000	Revenue: 1194000 Open source
20172017-12-31	Revenue	72000	Revenue: 72000 Open source
20182018-12-31	Revenue	72000	Revenue: 72000 Open source
20192019-12-31	Revenue	6832000	Revenue: 6832000 Open source
20202020-12-31	Revenue	10006000	Revenue: 10006000 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 7669000 Open source
20152015-12-31	Year over year	170.7%	Revenue: 20759000 Open source Revenue: 7669000 Open source
20162016-12-31	Year over year	-94.2%	Revenue: 1194000 Open source Revenue: 20759000 Open source
20172017-12-31	Year over year	-94%	Revenue: 72000 Open source Revenue: 1194000 Open source
20182018-12-31	Year over year	0%	Revenue: 72000 Open source Revenue: 72000 Open source
20192019-12-31	Year over year	9,388.9%	Revenue: 6832000 Open source Revenue: 72000 Open source
20202020-12-31	Year over year	46.5%	Revenue: 10006000 Open source Revenue: 6832000 Open source
20212021-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 10006000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -141.5% 2020

Net margin -157.2% 2020

Free cash flow margin -125.3% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	-585.6%	Operating Income: -44910000 Open source Revenue: 7669000 Open source
20152015-12-31	Operating margin	-263.8%	Operating Income: -54758000 Open source Revenue: 20759000 Open source
20162016-12-31	Operating margin	-6,826%	Operating Income: -81502000 Open source Revenue: 1194000 Open source
20172017-12-31	Operating margin	-97,404.2%	Operating Income: -70131000 Open source Revenue: 72000 Open source
20182018-12-31	Operating margin	-64,948.6%	Operating Income: -46763000 Open source Revenue: 72000 Open source
20192019-12-31	Operating margin	-246.4%	Operating Income: -16834000 Open source Revenue: 6832000 Open source
20202020-12-31	Operating margin	-141.5%	Operating Income: -14155000 Open source Revenue: 10006000 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -27816000 Open source Revenue: 0 Open source
20142014-12-31	Net margin	-739.1%	Net Income: -56680000 Open source Revenue: 7669000 Open source
20152015-12-31	Net margin	-268.5%	Net Income: -55748000 Open source Revenue: 20759000 Open source
20162016-12-31	Net margin	-6,853.9%	Net Income: -81836000 Open source Revenue: 1194000 Open source
20172017-12-31	Net margin	-99,868.1%	Net Income: -71905000 Open source Revenue: 72000 Open source
20182018-12-31	Net margin	-67,651.4%	Net Income: -48709000 Open source Revenue: 72000 Open source
20192019-12-31	Net margin	-272.1%	Net Income: -18592000 Open source Revenue: 6832000 Open source
20202020-12-31	Net margin	-157.2%	Net Income: -15730000 Open source Revenue: 10006000 Open source
20212021-12-31	Net margin	Not reported	Net Income: -27808000 Open source Revenue: 0 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 7669000 Open source
20152015-12-31	Free cash flow margin	-246.7%	Revenue: 20759000 Open source Operating Cash Flow: -49859000 Open source Capital Expenditure: 1363000 Open source
20162016-12-31	Free cash flow margin	-4,840.5%	Revenue: 1194000 Open source Operating Cash Flow: -56882000 Open source Capital Expenditure: 913000 Open source
20172017-12-31	Free cash flow margin	-82,050%	Revenue: 72000 Open source Operating Cash Flow: -58773000 Open source Capital Expenditure: 303000 Open source
20182018-12-31	Free cash flow margin	-60,131.9%	Revenue: 72000 Open source Operating Cash Flow: -43273000 Open source Capital Expenditure: 22000 Open source
20192019-12-31	Free cash flow margin	-293.4%	Revenue: 6832000 Open source Operating Cash Flow: -19821000 Open source Capital Expenditure: 221000 Open source
20202020-12-31	Free cash flow margin	-125.3%	Revenue: 10006000 Open source Operating Cash Flow: -12536000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -24128000 Open source Capital Expenditure: 251000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -24.1M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	Not reported	No source recorded
20152015-12-31	Operating cash flow	-49859000	Operating Cash Flow: -49859000 Open source
20162016-12-31	Operating cash flow	-56882000	Operating Cash Flow: -56882000 Open source
20172017-12-31	Operating cash flow	-58773000	Operating Cash Flow: -58773000 Open source
20182018-12-31	Operating cash flow	-43273000	Operating Cash Flow: -43273000 Open source
20192019-12-31	Operating cash flow	-19821000	Operating Cash Flow: -19821000 Open source
20202020-12-31	Operating cash flow	-12536000	Operating Cash Flow: -12536000 Open source
20212021-12-31	Operating cash flow	-24128000	Operating Cash Flow: -24128000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -24.4M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	Unavailable	No source recorded
20152015-12-31	Free cash flow	-51222000	Operating Cash Flow: -49859000 Open source Capital Expenditure: 1363000 Open source
20162016-12-31	Free cash flow	-57795000	Operating Cash Flow: -56882000 Open source Capital Expenditure: 913000 Open source
20172017-12-31	Free cash flow	-59076000	Operating Cash Flow: -58773000 Open source Capital Expenditure: 303000 Open source
20182018-12-31	Free cash flow	-43295000	Operating Cash Flow: -43273000 Open source Capital Expenditure: 22000 Open source
20192019-12-31	Free cash flow	-20042000	Operating Cash Flow: -19821000 Open source Capital Expenditure: 221000 Open source
20202020-12-31	Free cash flow	-12536000	Operating Cash Flow: -12536000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow	-24379000	Operating Cash Flow: -24128000 Open source Capital Expenditure: 251000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

19.7% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Liabilities / assets	23%	Total Liabilities: 39466000 Open source Total Assets: 171480000 Open source
20152015-12-31	Liabilities / assets	12.1%	Total Liabilities: 17005000 Open source Total Assets: 141083000 Open source
20162016-12-31	Liabilities / assets	44.3%	Total Liabilities: 44586000 Open source Total Assets: 100661000 Open source
20172017-12-31	Liabilities / assets	54.7%	Total Liabilities: 42593000 Open source Total Assets: 77809000 Open source
20182018-12-31	Liabilities / assets	121%	Total Liabilities: 33781000 Open source Total Assets: 27927000 Open source
20192019-12-31	Liabilities / assets	52.4%	Total Liabilities: 22066000 Open source Total Assets: 42081000 Open source
20202020-12-31	Liabilities / assets	30.8%	Total Liabilities: 11578000 Open source Total Assets: 37604000 Open source
20212021-12-31	Liabilities / assets	19.7%	Total Liabilities: 13496000 Open source Total Assets: 68454000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

12.48× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	4.69×	Current Assets: 164951000 Open source Current Liabilities: 35192000 Open source
20152015-12-31	Current assets / current liabilities	10.63×	Current Assets: 134258000 Open source Current Liabilities: 12632000 Open source
20162016-12-31	Current assets / current liabilities	6.34×	Current Assets: 87474000 Open source Current Liabilities: 13807000 Open source
20172017-12-31	Current assets / current liabilities	2.05×	Current Assets: 66736000 Open source Current Liabilities: 32600000 Open source
20182018-12-31	Current assets / current liabilities	0.72×	Current Assets: 19295000 Open source Current Liabilities: 26646000 Open source
20192019-12-31	Current assets / current liabilities	1.87×	Current Assets: 40407000 Open source Current Liabilities: 21598000 Open source
20202020-12-31	Current assets / current liabilities	3.17×	Current Assets: 36730000 Open source Current Liabilities: 11578000 Open source
20212021-12-31	Current assets / current liabilities	12.48×	Current Assets: 65235000 Open source Current Liabilities: 5227000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 55.75 million Exact value Exact value: -55748000 USD 2015-01-01 – 2015-12-31: -55748000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2015-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -55748000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -55748000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828018002874/rgls-20171231.xml#243902 Filing: 000162828018002874 The citation records this snapshot. The page link may show a newer release later.	−USD 49.86 million Exact value Exact value: -49859000 USD 2015-01-01 – 2015-12-31: -49859000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2015-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -49859000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49859000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828018002874/rgls-20171231.xml#243266 Filing: 000162828018002874 The citation records this snapshot. The page link may show a newer release later.	USD 1.36 million Exact value Exact value: 1363000 USD 2015-01-01 – 2015-12-31: 1363000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2015-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 1363000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1363000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828018002874/rgls-20171231.xml#257122 Filing: 000162828018002874 The citation records this snapshot. The page link may show a newer release later.	−USD 51.22 million Calculation and evidence -49859000 − 1363000 USD Exact free cash flow: -51222000 USD 2015-01-01 – 2015-12-31: -49859000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1363000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2015-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -51222000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49859000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828018002874/rgls-20171231.xml#243266 Filing: 000162828018002874 Input fundies:CapitalExpenditure: 1363000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828018002874/rgls-20171231.xml#257122 Filing: 000162828018002874 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 81.84 million Exact value Exact value: -81836000 USD 2016-01-01 – 2016-12-31: -81836000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2016-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -81836000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -81836000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#229439 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.	−USD 56.88 million Exact value Exact value: -56882000 USD 2016-01-01 – 2016-12-31: -56882000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2016-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -56882000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -56882000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#228803 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.	USD 913,000 Exact value Exact value: 913000 USD 2016-01-01 – 2016-12-31: 913000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2016-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 913000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 913000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#241585 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.	−USD 57.8 million Calculation and evidence -56882000 − 913000 USD Exact free cash flow: -57795000 USD 2016-01-01 – 2016-12-31: -56882000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 913000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2016-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -57795000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -56882000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#228803 Filing: 000162828019003037 Input fundies:CapitalExpenditure: 913000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#241585 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 71.91 million Exact value Exact value: -71905000 USD 2017-01-01 – 2017-12-31: -71905000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2017-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -71905000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -71905000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#230432 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.	−USD 58.77 million Exact value Exact value: -58773000 USD 2017-01-01 – 2017-12-31: -58773000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2017-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -58773000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -58773000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#229015 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.	USD 303,000 Exact value Exact value: 303000 USD 2017-01-01 – 2017-12-31: 303000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2017-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 303000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 303000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#241794 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.	−USD 59.08 million Calculation and evidence -58773000 − 303000 USD Exact free cash flow: -59076000 USD 2017-01-01 – 2017-12-31: -58773000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 303000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2017-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -59076000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -58773000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#229015 Filing: 000162828019003037 Input fundies:CapitalExpenditure: 303000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828019003037/rgls-20181231.xml#241794 Filing: 000162828019003037 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 48.71 million Exact value Exact value: -48709000 USD 2018-01-01 – 2018-12-31: -48709000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2018-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -48709000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48709000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828020003483/rgls-20191231.xml#208884 Filing: 000162828020003483 The citation records this snapshot. The page link may show a newer release later.	−USD 43.27 million Exact value Exact value: -43273000 USD 2018-01-01 – 2018-12-31: -43273000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2018-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -43273000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43273000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828020003483/rgls-20191231.xml#207845 Filing: 000162828020003483 The citation records this snapshot. The page link may show a newer release later.	USD 22,000 Exact value Exact value: 22000 USD 2018-01-01 – 2018-12-31: 22000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2018-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 22000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828020003483/rgls-20191231.xml#219818 Filing: 000162828020003483 The citation records this snapshot. The page link may show a newer release later.	−USD 43.3 million Calculation and evidence -43273000 − 22000 USD Exact free cash flow: -43295000 USD 2018-01-01 – 2018-12-31: -43273000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 22000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2018-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -43295000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43273000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828020003483/rgls-20191231.xml#207845 Filing: 000162828020003483 Input fundies:CapitalExpenditure: 22000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828020003483/rgls-20191231.xml#219818 Filing: 000162828020003483 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 18.59 million Exact value Exact value: -18592000 USD 2019-01-01 – 2019-12-31: -18592000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2019-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -18592000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18592000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828021004294/rgls-20201231.htm#1067744 Filing: 000162828021004294 The citation records this snapshot. The page link may show a newer release later.	−USD 19.82 million Exact value Exact value: -19821000 USD 2019-01-01 – 2019-12-31: -19821000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2019-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -19821000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19821000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828021004294/rgls-20201231.htm#1100779 Filing: 000162828021004294 The citation records this snapshot. The page link may show a newer release later.	USD 221,000 Exact value Exact value: 221000 USD 2019-01-01 – 2019-12-31: 221000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2019-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 221000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 221000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828021004294/rgls-20201231.htm#1104196 Filing: 000162828021004294 The citation records this snapshot. The page link may show a newer release later.	−USD 20.04 million Calculation and evidence -19821000 − 221000 USD Exact free cash flow: -20042000 USD 2019-01-01 – 2019-12-31: -19821000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 221000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2019-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -20042000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19821000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828021004294/rgls-20201231.htm#1100779 Filing: 000162828021004294 Input fundies:CapitalExpenditure: 221000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828021004294/rgls-20201231.htm#1104196 Filing: 000162828021004294 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 15.73 million Exact value Exact value: -15730000 USD 2020-01-01 – 2020-12-31: -15730000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2020-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -15730000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15730000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828022005771/rgls-20211231.htm#1075226 Filing: 000162828022005771 The citation records this snapshot. The page link may show a newer release later.	−USD 12.54 million Exact value Exact value: -12536000 USD 2020-01-01 – 2020-12-31: -12536000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2020-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -12536000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12536000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828022005771/rgls-20211231.htm#1110789 Filing: 000162828022005771 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2020-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828022005771/rgls-20211231.htm#1114185 Filing: 000162828022005771 The citation records this snapshot. The page link may show a newer release later.	−USD 12.54 million Calculation and evidence -12536000 − 0 USD Exact free cash flow: -12536000 USD 2020-01-01 – 2020-12-31: -12536000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2020-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -12536000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12536000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828022005771/rgls-20211231.htm#1110789 Filing: 000162828022005771 Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828022005771/rgls-20211231.htm#1114185 Filing: 000162828022005771 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 27.81 million Exact value Exact value: -27808000 USD 2021-01-01 – 2021-12-31: -27808000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2021-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -27808000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27808000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828023009061/rgls-20221231.htm#969269 Filing: 000162828023009061 The citation records this snapshot. The page link may show a newer release later.	−USD 24.13 million Exact value Exact value: -24128000 USD 2021-01-01 – 2021-12-31: -24128000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2021-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -24128000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24128000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828023009061/rgls-20221231.htm#994874 Filing: 000162828023009061 The citation records this snapshot. The page link may show a newer release later.	USD 251,000 Exact value Exact value: 251000 USD 2021-01-01 – 2021-12-31: 251000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2021-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 251000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 251000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828023009061/rgls-20221231.htm#1000308 Filing: 000162828023009061 The citation records this snapshot. The page link may show a newer release later.	−USD 24.38 million Calculation and evidence -24128000 − 251000 USD Exact free cash flow: -24379000 USD 2021-01-01 – 2021-12-31: -24128000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 251000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2021-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -24379000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24128000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828023009061/rgls-20221231.htm#994874 Filing: 000162828023009061 Input fundies:CapitalExpenditure: 251000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828023009061/rgls-20221231.htm#1000308 Filing: 000162828023009061 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 28.32 million Exact value Exact value: -28323000 USD 2022-01-01 – 2022-12-31: -28323000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2022-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -28323000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28323000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828024012543/rgls-20231231.htm#932502 Filing: 000162828024012543 The citation records this snapshot. The page link may show a newer release later.	−USD 25.53 million Exact value Exact value: -25526000 USD 2022-01-01 – 2022-12-31: -25526000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2022-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -25526000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25526000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828024012543/rgls-20231231.htm#952586 Filing: 000162828024012543 The citation records this snapshot. The page link may show a newer release later.	USD 361,000 Exact value Exact value: 361000 USD 2022-01-01 – 2022-12-31: 361000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2022-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 361000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 361000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828024012543/rgls-20231231.htm#957652 Filing: 000162828024012543 The citation records this snapshot. The page link may show a newer release later.	−USD 25.89 million Calculation and evidence -25526000 − 361000 USD Exact free cash flow: -25887000 USD 2022-01-01 – 2022-12-31: -25526000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 361000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2022-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -25887000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25526000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828024012543/rgls-20231231.htm#952586 Filing: 000162828024012543 Input fundies:CapitalExpenditure: 361000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828024012543/rgls-20231231.htm#957652 Filing: 000162828024012543 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 30.04 million Exact value Exact value: -30037000 USD 2023-01-01 – 2023-12-31: -30037000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2023-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -30037000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30037000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#963833 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.	−USD 26.77 million Exact value Exact value: -26768000 USD 2023-01-01 – 2023-12-31: -26768000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2023-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -26768000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26768000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#985197 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.	USD 613,000 Exact value Exact value: 613000 USD 2023-01-01 – 2023-12-31: 613000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2023-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 613000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 613000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#990263 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.	−USD 27.38 million Calculation and evidence -26768000 − 613000 USD Exact free cash flow: -27381000 USD 2023-01-01 – 2023-12-31: -26768000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 613000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2023-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -27381000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26768000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#985197 Filing: 000162828025012627 Input fundies:CapitalExpenditure: 613000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#990263 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 46.36 million Exact value Exact value: -46358000 USD 2024-01-01 – 2024-12-31: -46358000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGULUS THERAPEUTICS INC. · 2024-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Net Income: -46358000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -46358000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#963050 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.	−USD 41.67 million Exact value Exact value: -41673000 USD 2024-01-01 – 2024-12-31: -41673000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGULUS THERAPEUTICS INC. · 2024-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Operating Cash Flow: -41673000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41673000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#984534 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.	USD 340,000 Exact value Exact value: 340000 USD 2024-01-01 – 2024-12-31: 340000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGULUS THERAPEUTICS INC. · 2024-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Capital Expenditure: 340000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 340000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#989699 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.	−USD 42.01 million Calculation and evidence -41673000 − 340000 USD Exact free cash flow: -42013000 USD 2024-01-01 – 2024-12-31: -41673000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 340000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGULUS THERAPEUTICS INC. · 2024-12-31 REGULUS THERAPEUTICS INC. (edgar:1505512) Free cash flow: -42013000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:41:17Z Snapshot: 30af778fcb9b60fab88155c9b11145c95bc8386072bbd531e04c8d4285f5401d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1505512?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41673000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#984534 Filing: 000162828025012627 Input fundies:CapitalExpenditure: 340000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1505512/000162828025012627/rgls-20241231.htm#989699 Filing: 000162828025012627 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

88 filings · 3,545 latest values · 3,545 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001505512, 1505512, RGLS, edgar:1505512

Also known as REGULUS THERAPEUTICS INC., Regulus Therapeutics Inc.

REGULUS THERAPEUTICS INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation